227 related articles for article (PubMed ID: 34363938)
1. The inhibitors of KDM4 and KDM6 histone lysine demethylases enhance the anti-growth effects of erlotinib and HS-173 in head and neck cancer cells.
Kleszcz R; Skalski M; Krajka-Kuźniak V; Paluszczak J
Eur J Pharm Sci; 2021 Nov; 166():105961. PubMed ID: 34363938
[TBL] [Abstract][Full Text] [Related]
2. Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells.
Kleszcz R; Frąckowiak M; Dorna D; Paluszczak J
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445628
[TBL] [Abstract][Full Text] [Related]
3. The Emerging Significance of Histone Lysine Demethylases as Prognostic Markers and Therapeutic Targets in Head and Neck Cancers.
Dorna D; Paluszczak J
Cells; 2022 Mar; 11(6):. PubMed ID: 35326475
[TBL] [Abstract][Full Text] [Related]
4. HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
Foki E; Stanisz I; Kadletz L; Kotowski U; Seemann R; Schmid R; Heiduschka G
Wien Klin Wochenschr; 2021 Jan; 133(1-2):26-31. PubMed ID: 32876741
[TBL] [Abstract][Full Text] [Related]
5. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
6. Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.
Zheng Y; Wang Z; Ding X; Dong Y; Zhang W; Zhang W; Zhong Y; Gu W; Wu Y; Song X
Cell Prolif; 2018 Jun; 51(3):e12424. PubMed ID: 29232766
[TBL] [Abstract][Full Text] [Related]
7.
Anisuzzaman AS; Haque A; Wang D; Rahman MA; Zhang C; Chen Z; Chen ZG; Shin DM; Amin AR
Mol Cancer Ther; 2017 Apr; 16(4):729-738. PubMed ID: 28119490
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab.
Hartmann S; Neckel N; Seher A; Mutzbauer G; Brands RC; Linz C; Kübler AC; Müller-Richter UD
Clin Oral Investig; 2016 May; 20(4):759-69. PubMed ID: 26297130
[TBL] [Abstract][Full Text] [Related]
9. 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
Sobhakumari A; Orcutt KP; Love-Homan L; Kowalski CE; Parsons AD; Knudson CM; Simons AL
Oncol Res; 2016; 24(1):55-64. PubMed ID: 27178822
[TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of KDM6 histone demethylases eradicates tumor-initiating cells via enhancer reprogramming in colorectal cancer.
Zhang J; Ying Y; Li M; Wang M; Huang X; Jia M; Zeng J; Ma C; Zhang Y; Li C; Wang X; Shu XS
Theranostics; 2020; 10(22):10016-10030. PubMed ID: 32929331
[TBL] [Abstract][Full Text] [Related]
11. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
[No Abstract] [Full Text] [Related]
12. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
[TBL] [Abstract][Full Text] [Related]
13. MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.
Wen Y; Li H; Zeng Y; Wen W; Pendleton KP; Lui VW; Egloff AM; Grandis JR
Oncotarget; 2016 Apr; 7(17):23300-11. PubMed ID: 27004400
[TBL] [Abstract][Full Text] [Related]
14. Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma.
Stanam A; Love-Homan L; Joseph TS; Espinosa-Cotton M; Simons AL
Mol Oncol; 2015 Aug; 9(7):1371-83. PubMed ID: 25888065
[TBL] [Abstract][Full Text] [Related]
15. Phospho-EGFRTyr992 is synergistically repressed by co-inhibition of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K), which attenuates resistance to erlotinib in head and neck cancer cells.
Chen X; Gao W; Yin G; Guo W; Huang J; Huang Z; Zhang Y
Ann Transl Med; 2021 Sep; 9(18):1455. PubMed ID: 34734007
[TBL] [Abstract][Full Text] [Related]
16. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
[TBL] [Abstract][Full Text] [Related]
17. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
Boeckx C; Van den Bossche J; De Pauw I; Peeters M; Lardon F; Baay M; Wouters A
BMC Res Notes; 2015 Jun; 8():203. PubMed ID: 26032726
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma.
Ma H; Jin S; Yang W; Zhou G; Zhao M; Fang S; Zhang Z; Hu J
Br J Cancer; 2018 Feb; 118(4):509-521. PubMed ID: 29348488
[TBL] [Abstract][Full Text] [Related]
19. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
20. Osthole induces cell cycle arrest and apoptosis in head and neck squamous cell carcinoma by suppressing the PI3K/AKT signaling pathway.
Yang J; Zhu XJ; Jin MZ; Cao ZW; Ren YY; Gu ZW
Chem Biol Interact; 2020 Jan; 316():108934. PubMed ID: 31870840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
